Bupaq 0,3 mg/ml Injektionslösung für Hunde und Katzen

Authorised

- Buprenorphine hydrochloride

Product identification

Medicine name:
Bupaq 0,3 mg/ml Injektionslösung für Hunde und Katzen
Bupaq 0,3 mg/ml, Ενέσιμο διάλυμα για σκύλους και γάτες

Active substance:
Buprenorphine hydrochloride

Target species:
Dog
Cat

Route of administration:
Intramuscular use
Intravenous use

Product details

Active substance and strength:
Buprenorphine hydrochloride
0.32 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QN02AE01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Package description:
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 10 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 3 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 4 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 5 vials of 2 ml
Clear glass vials type II, coated bromobutyl rubber stopper type I, aluminium cap, packed in a cardboard box. Package size: Cardboard box with 6 vials of 2 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Vetviva Richter GmbH

Marketing authorisation date:

15/01/2019

Manufacturing sites for batch release:
Vetviva Richter GmbH

Responsible authority:
National Organization For Medicines

Authorisation number:
26899/01-10-2018/16-01-2019/K-0233801

Date of authorisation status change:
25/08/2020

Reference member state:
Austria

Procedure number:
AT/V/0008/002

Concerned member states:
Bulgaria Denmark Estonia France Germany Greece Hungary Latvia Lithuania Norway Portugal Romania Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet